Exploration panel | Validation panel | PSC E versus V | HC E versus V | |||||
---|---|---|---|---|---|---|---|---|
PSC (N=41) | HC (N=124) | p Value | PSC (N=44) | HC (N=139) | p Value | p Value | p Value | |
Age, median years (min–max) | 50.0 (23–82) | 46.0 (31–61) | 0.12 | 48.0 (21–69) | 47.0 (30–61) | 0.15 | 0.94 | 0.40 |
Sex, male (%) | 24 (58.5) | 51 (41.1) | 0.07 | 29 (65.9) | 57 (41.0) | <0.01 | 0.51 | 1.00 |
BMI, median kg/m2 (min–max) | 25.5 (18–37) | 25.9 (18–39) | 0.86 | 24.4 (18–38) | 25.5 (19–43) | 0.17 | 0.80 | 0.61 |
Smoking, yes (%) | 1 (2.4) | 17 (13.7) | <0.05 | 1 (2.3) | 13 (9.4) | 0.19 | 1.00 | 0.33 |
Sample time in RT, median hours (min–max) | 27.0 (15–63) | 32.0 (18–72) | 0.51 | 27.5 (13–59) | 34.0 (16–71) | 0.28 | 1.00 | 0.65 |
Courses of AB <12 months, median (min–max) | 0 (0–7) | 0 (0–5) | 0.18 | 0.0 (0–10) | 0 (0–3) | 0.79 | 0.15 | 0.82 |
UC, n (%) | 19 (46.3) | 25 (56.8) | 0.39 | |||||
Crohn's disease, n (%) | 8 (19.5) | 3 (6.8) | 0.11 | |||||
Medication, yes, n (%) | ||||||||
PPI | 4 (9.8) | 12 (9.7) | 1.00 | 2 (4.5) | 6 (4.3) | 1.00 | 0.42 | 0.09 |
Antihistamines | 2 (4.9) | 8 (6.5) | 1.00 | 4 (9.1) | 6 (4.3) | 0.26 | 0.68 | 0.58 |
Statins | 3 (7.3) | 5 (4.0) | 0.41 | 4 (9.1) | 6 (4.3) | 0.26 | 1.00 | 1.00 |
Ursodeoxycholic acid | 13 (31.7) | 12 (27.3) | 0.81 | |||||
Prednisolon | 4 (9.8) | 9 (20.5) | 0.23 | |||||
5-ASA | 19 (46.3) | 16 (36.4) | 0.39 | |||||
Infliximab | 1 (2.3) | 1.00 | ||||||
Azathioprine | 4 (9.8) | 8 (18.2) | 0.36 | |||||
Budesonide | 2 (4.9) | 1 (2.3) | 0.61 | |||||
Disease-specific variables | Available for | |||||||
PSC disease duration, median years (min–max) | 10.6 (1–32) | 6.6 (1–26) | 0.12 | N=85 | ||||
IBD duration, median years (min–max) | 10.3 (0–41) | 11.9 (2–45) | 0.95 | N=63 | ||||
Other autoimmune diseases, yes (%) | 12 (29.3) | 11 (25.0) | 0.63 | N=80 | ||||
Mayo risk score, median (min–max) | −0.04 (−1.5–3.2) | −0.06 (−1.9–3.3) | 0.98 | N=64 | ||||
P-ANCA status, positive (%) | 21 (51.2) | 23 (52.3) | 0.65 | N=77 | ||||
Platelet count, 109/L, median (min–max) | 210 (57–578) | 256 (62–432) | <0.05 | N=77 | ||||
Creatinine, µmol/L, median (min–max) | 69 (42–106) | 68 (42–100) | 0.98 | N=78 | ||||
Bilirubin, µmol/L, median (min–max) | 13 (5–101) | 13 (3–114) | 0.61 | N=77 | ||||
Albumin, g/L, median (min–max) | 43 (24–47) | 43 (16–47) | 0.26 | N=72 | ||||
INR, median (min–max) | 1.0 (0.9–1.3) | 1.0 (0.9–1.3) | 0.44 | N=68 | ||||
AST, U/L, median (min–max) | 59 (19–197) | 43 (18–172) | 0.49 | N=72 | ||||
ALT, U/L, median (min–max) | 59 (14–331) | 48 (14–320) | 0.66 | N=78 | ||||
ALP, U/L, median (min–max) | 178 (50–598) | 142 (30–589) | 0.40 | N=77 | ||||
GGT, U/L, median (min–max) | 201 (10–1576) | 175 (12–1091) | 0.86 | N=76 |
AB, antibiotics; ALP, alkaline phosphatase; ALT, alanine aminotransferase; 5-ASA, 5-Aminosalicylic acid; AST, aspartate aminotransferase; BMI, body mass index; E, exploration panel; GGT, gamma-glutaryltransferase; HC, healthy controls; INR, international normalised ratio; P-ANCA, perinuclear anti-neutrophil cytoplasmic antibodies; PPI, proton pump inhibitors; PSC, primary sclerosing cholangitis; RT, room temperature; V, validation panel.